California-based Zipline, a medical products delivery firm, has raised $190 million that it will use to establish health care logistics sites in Rwanda and Ghana. Zipline is working with the governments of the two countries to deliver blood products and other supplies using drones.
German biotech Affimed announced the termination of its early-stage program for hematology treatment candidate AFM11. "We have determined that the optimal use of our resources at this time is to advance our innate cell engagers, focusing their development on indications with high unmet need and the potential for a rapid path to regulatory approval," said CEO Dr. Adi Hoess.
The NIH awarded a $1.8 million, two-year grant to Sage Science for the advancement of its DNA preparation technology that uses CRISPR-Cas9 for targeted long-read sequencing.
A Series B funding round has pulled in $15 million for Paradigm Diagnostics. Proceeds will be used to expedite the launch of Paradigm Cancer Diagnostic, the company's flagship product.
A multigene liquid biopsy platform for detecting lung cancer has been launched by Biocept. The Target Selector NGS Lung Panel, which runs on Thermo Fisher Scientific's Ion Torrent next-generation sequencing platform, can be used to identify and monitor actionable lung cancer-related biomarkers.
Kurin has obtained CE mark approval for its Kurin Lock specimen diversion device, which is designed to divert the initial portion of blood, which can contain contaminants, during each draw.
A study of Department of Veterans Affairs data in the journal Blood found that multiple myeloma patients who were African American had longer median overall survival than white patients (5.07 years compared with 4.52), with age at diagnosis being a key factor. Other studies have found lower overall survival for African Americans, possibly due to disparities in access to novel treatments, which were not found among the VA patients in the current study.
Patients who received allogeneic hematopoietic cell transplantation and high-dose total body irradiation were almost eight times as likely as the general population to develop a subsequent malignant neoplasm, according to a study in the journal Blood. The study involved 4,905 patients, 11% of whom had a total of 581 malignant neoplasms following their transplants.
Quotient has received FDA approval to commercialize seven more blood bank reagents for extended antigen typing.
The Democratic Republic of Congo says Ebola cases have reached 1,826 in the current outbreak. Meanwhile, GAVI, the Vaccine Alliance, said it will spend an additional $9.2 million in support of a vaccination campaign.
- Page 1